Abstract YO18
Case summary
Case Details - A 47-year-old female, a known case of multicentric Glioblastoma multiforme (grade four) who had received concurrent chemoradiotherapy followed by palliative Temozolomide on tapering doses of Levetiracetam and had been commenced on Phenytoin presented (during the peak of the second wave of Pandemic) with complaints of new-onset maculopapular lesions involving legs, arms, and lower back. She subsequently developed a worsening Rash with the development of vesico-bullous lesions, oral mucosal lesions, acral involvement, and systemic symptoms (Fever) 2 days later. Arrangements were made to obtain a Tele Dermatology consult (from a Private setting) following which a diagnosis of SJS TENS Overlap was made. A consult with the Medical Oncology department was sought in order to provide ICU admission which was refused. She was subsequently admitted under Palliative Medicine after obtaining high-risk consent. Her lesions regressed with supportive management comprising Cyclosporin, and intravenous antibiotics, however, her general condition deteriorated. She was discharged as she had expressed a wish to meet her mother (at home). However, she was unable to obtain a fitness for Air travel. She was re-admitted and re-started on supportive treatment (symptom-directed medications via intravenous route). A subcutaneous line was inserted in the anterior chest wall and pre-filled syringes containing essential pain medication, anti-seizure medication (sc bolus levetiracetam), and dexamethasone for three days were provided to the Patient’s husband who had volunteered to take her back home via Train.
Discussion - Important Issues included Logistical - Lack of infrastructure, Medical - use of boluses of subcutaneous medication at end of life (without syringe drivers).
Conclusion - Practical Issues related to Travel, Finances, and Continuity of care may assume more importance than Spirituality underlining the importance of formulating a comprehensive management plan most suited to the Patient and their Family members.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
439P - Evaluating Ewing’s sarcoma as the prototype for cancer care in teenage and young adults (TYA): A single-center retrospective cross-sectional study
Presenter: Pradeep Kumar Kistampally
Session: Poster viewing 06
440P - Targeting KRAS<sup>G12C</sup>: Repurposing of potential therapeutics for the treatment of pancreatic ductal adenocarcinoma (PDAC)
Presenter: EVA RAHMAN KABIR
Session: Poster viewing 06
441P - Malignant diseases diagnosed in people living with HIV in Japan
Presenter: Kenju Ando
Session: Poster viewing 06
442P - Dose intensity and tolerance of modified FOLFIRINOX in patients with advanced cancer
Presenter: Tejaswini Adadadara
Session: Poster viewing 06
444P - Incidence of cancer diagnosis and cancer care before and after the COVID-19 pandemic in French Polynesia TEAHUPOO study
Presenter: Elodie HIRIGOYEN
Session: Poster viewing 06
445P - Development of a simple and objective prognostication model in patients with advanced solid malignant tumor treated with immune checkpoint inhibitors: A pan-cancer analysis
Presenter: Yuto Matsushita
Session: Poster viewing 06
446P - Impact of previous immunotherapy on chemotherapy efficacy in metastatic melanoma
Presenter: Meiyu Fang
Session: Poster viewing 06
447P - Clinical characteristics of 21 patients with type 1 diabetes mellitus related to immune checkpoint inhibitors
Presenter: Haruna Kameoka
Session: Poster viewing 06
448P - Prevalence of thyroid dysfunction, diabetes, and impact of palliative chemotherapy in advanced metastatic cancer patients: Prospective data from LMIC
Presenter: Amit Sehrawat
Session: Poster viewing 06
449P - The study of androgen receptor status in triple negative breast cancer patients at Medical Oncology Department, Yangon General Hospital (YGH)
Presenter: Khin Mu
Session: Poster viewing 06